John Crown, MB, BCh, BAO, BSc, MD, MBA, discusses the rationale for evaluating lapatinib (Tykerb) with standard trastuzumab/chemotherapy regimen in patients with HER2-positive breast cancer, as well as contextualizes results from a phase 2 trial.
John Crown, BCh, BAO, BSc, MD, MBA
Advertisement
Articles by John Crown, BCh, BAO, BSc, MD, MBA
John Crown, BCh, BAO, BSc, MD, MBA, discusses the role of eribulin mesylate in triple-negative breast cancer.
Advertisement
Latest Updated Articles
Dr. Crown on the Role of Eribulin Mesylate in TNBCSeptember 17th 2020
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Capivasertib Plus Abiraterone and Prednisone for PTEN-Deficient mHSPC
2
MONUMENTAL-3 Data Support Talquetamab Plus Daratumumab ± Pomalidomide as a New SOC in R/R Myeloma
3
Luspatercept Misses Primary RBC-TI End Point But Shows Clinically Meaningful Improvement for Anemia in Myelofibrosis
4
FDA Approves Adjuvant Belzutifan Plus Pembrolizumab in ccRCC
5